



2024/11/15

產業類別	橡膠	
投資建議	中立	
收盤價	NT\$ 23.35	目標價
		NT\$

本次報告：法說會

交易資料

潛在報酬率 (%)	--
52 週還原收盤價區間 (NT\$)	20.75-25.35
市值 (NT\$百萬元)	19280
市值 (US\$百萬美元)	593
流通在外股數 (百萬股)	826.00
董監持股 (%)	14.15
外資持股 (%)	27.08
投信持股 (%)	0.04
融資使用率 (%)	3.29

財務資料

	2023
股東權益 (NT\$百萬元)	19,422
ROA (%)	1.82
ROE (%)	3.58
淨負債比率 (%)	45.24

公司簡介

台橡為各種合成橡膠及應用材料之製造商，其主要產品為苯乙烯橡膠(SBR)、丁二烯橡膠(BR)、熱可塑性橡膠(TPE)。公司 2023 年合成橡膠銷量 53.21 萬噸，營收占比 97.7%，非合成橡膠產品銷量 8,856 噸，營收占比 2.3%。

葉家宏 bill.yeh@sinopac.com

台橡 (2103 TT)

丁二烯報價回落，靜待原料穩定及供需改善


永豐觀點

受惠丁二烯報價走強，台橡 3Q24 營收繳出 1Q13 以來最佳表現，但丁二烯報價於近期出現回落，將拖累台橡營運表現，且公司對 2025 展望前景保守，研究處對台橡持中立看法。

投資評價與建議


研究處給台橡中立投資建議：丁二烯報價下跌將拖累台橡 4Q24 獲利表現，且 2025 年產業展望不確定性仍高，考量丁二烯報價下檔有限，且橡膠產業仍處在供過於求格局，台橡獲利表現將承壓，目前 PBR 評價僅 0.95X，接近歷史低線 PBR 0.87X，但因丁二烯報價走勢波動，且明年需求也未能有顯著成長，給予投資建議中立。

近八季營收及 YoY 趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Nov. 2024

近八季營業利益及毛利率趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Nov. 2024

營運現況與分析

台橡為合成橡膠生產廠商：台橡為各種合成橡膠及應用材料之製造商，其主要產品為苯乙烯橡膠(SBR)、丁二烯橡膠(BR)、熱可塑性橡膠(TPE)，公司 2023 年合成橡膠銷量 53.21 萬噸，營收占比 97.7%，非合成橡膠產品銷量 8,856 噸，營收占比 2.3%。

圖一：公司主要產品及其用途

乳聚苯乙烯-丁二烯橡膠 (E-SBR)	一般型汽車輪胎、鞋底、輸送帶、膠管、運動器材、玩具及其它工業用製品。
溶聚苯乙烯-丁二烯橡膠 (S-SBR)	節能(低滾動阻力)輪胎、高性能輪胎、冬季胎及全天候輪胎。
聚丁二烯/順丁橡膠 (BR)	高速胎、聚苯乙烯改質劑 (HIPS)、鞋底、運動器材、及其它工業製品。
熱可塑性彈性體 (TPE)	黏著劑、熱熔膠、塑膠改質劑、薄膜、醫療輸液用品、柏油改質及其他特殊應用工業製品。
應用材料 (Applied Materials)	高級鞋材、發泡鞋材、玩具、文具用品、電線電纜、嬰兒用品、個人保健、手工具包覆材料、汽車產業及冰箱邊條等產業。

資料來源：公司年報；永豐投顧研究處整理，Nov. 2024

3Q24 稅後 EPS 為 0.43 元：台橡 3Q24 營收 99.3 億元，(+11% QoQ，+29.2% YoY)，為 1Q13 以來最佳表現，主要受惠中國推行汽車舊換新政策，推動中國半鋼胎(PCR)開工率維持高檔水準，且原料丁二烯報價持續走強，推升營收表現成長，毛利率 10.53%(-1.44pts. QoQ，+1.07pts. YoY)，業外認列獲利 3.05 億元，主因認列股利收入 1.52 億元，及印度合資子公司 ISRPL 受惠丁二烯報價走升，有利合約公式報價所致，稅後淨利 3.53 億元(+8.7% QoQ，+123.1% YoY)，3Q24 稅後 EPS 0.43 元。


4Q24 丁二烯報價下跌，獲利表現增添壓力：展望 4Q24，歐盟對中國電動車加徵關稅，然對於中國國內輪胎廠需求未受影響，半鋼胎開工率仍約位於 79%左右的高檔水準，台橡合成橡膠需求維持穩健，但主要受到丁二烯報價近期自 10 月初高點 1,560 美元/噸連跌 6 週至 1,300 美元/噸(跌幅 16.7%)影響，合成橡膠及天然橡膠報價同步走弱，抵銷天然橡膠因天災造成供應較緊的現況，考量台橡約備有近一季的原料庫存，預期將使台橡營收及獲利表現承壓，研究處預估 4Q24 營收 94.24 億元，(-5.1% QoQ，+19.6% YoY)，預估毛利率 8.67%，(-1.86 pts. QoQ，-3.62 pts. YoY)，預估稅後淨利 8,265 萬元(-76.6% QoQ，-63.2% YoY)，稅後 EPS 0.1 元，研究處預估 2024 年營收 370.44 億元(+17.9%YoY)，毛利率 10.76%，稅後淨利 10.22 億元(+50.3%YoY)，稅後 EPS 1.24 元。

台橡中華化學搬遷案預計 1H25 完工，並增設 F-SSBR 產線：台橡中華化學搬遷案已於 10M24 如期完成機械竣工，1Q25 將進行試產，並預計於 1H25 完成新舊廠過度轉移，ESBR 年產能將從原先的 17 萬噸提升至 22 萬噸，阿朗台橡產能 NBR 產能則預計由原先的 3 萬噸提升至 4 萬噸。另外，台橡也已通過將於中國南通興建 F-SSBR 產線，主要為因應新能源車趨勢，擴大開發綠色輪胎產品，有利台橡長期獲利布局。

考量公司展望仍保守，且丁二烯仍位居高檔，給予投資評等中立：展望 2025，中國成長速度仍較為緩慢，台橡預期市場需求將與 2024 年相仿，難見需求大幅突破加上中國汽車舊換新政策將於 1M25 到期，屆時合成橡膠需求亦增添變數，而產業供過於求情況仍存，加上丁二烯於近期報價走勢下跌，同樣使台橡營運備感壓力，預期台橡營收將受丁二烯報價下跌影響而衰退，但考量亞洲輕裂廠開工率已低，丁二烯報價下檔空間應有限，將壓抑台橡獲利表現，因此對台橡獲利持保守看法。研究處預估 2025 年營收 329.87 億元(-11%YoY)，毛利率 10.64%，稅後淨

利 6.92 億元(-32.3%YoY) · 稅後 EPS 0.84 元 · 給予投資評等中立。

圖二：天然橡膠及丁二烯報價走勢開始下行



資料來源：CMoney；永豐投顧研究處整理 · Nov. 2024

附表一：當年度損益表

單位：百萬元	24Q1	24Q2	24Q3	24Q4F	2024F
營業收入	8,745	8,945	9,930	9,424	37,044
營業毛利	1,052	1,070	1,046	817	3,985
營業利益	416	415	316	87	1,170
稅前淨利	498	590	621	150	1,560
稅後純益	261	325	353	83	1,022
稅後 EPS (元)	0.32	0.39	0.43	0.1	1.24
營收 QoQ 成長率	10.95	2.28	11.01	-5.09	--
營收 YoY 成長率	7.79	15.53	29.15	19.56	17.88
毛利率	12.02	11.97	10.53	8.67	10.76
營益率	4.76	4.64	3.18	0.92	3.16
稅後純益率	3.48	4.17	4.04	0.88	2.76

資料來源：CMoney；永豐投顧研究處整理 · Nov. 2024

附表二：五個年度損益表

單位：百萬元	2021	2022	2023	2024F	2025F
營業收入	32,533	33,841	31,427	37,044	32,987
%變動率	35.42	4.02	-7.13	17.87	-10.95
營業毛利	6,800	5,513	3,308	3,985	3,511
毛利率 (%)	20.90	16.29	10.53	10.76	10.64
營業淨利	3,928	2,675	948	1,170	994
稅前淨利	5,633	3,069	1,424	1,560	1,257
%變動率	981.87	-45.52	-53.59	9.55	-19.42
稅後純益	3,931	1,783	680	1,022	692
%變動率	--	-54.65	-61.86	50.29	-32.29
稅後 EPS * (元)	4.76	2.16	0.82	1.24	0.84
市調 EPS * (元)	4.95	2.8	0.85	1.5	--
PER (x)	4.91	10.81	28.48	18.83	27.80
PBR (x)	1.07	1.04	0.99	0.93	0.93
每股淨值 * (元)	21.83	22.44	23.52	24.98	24.98
每股股利 (元)	2.40	1.08	0.56	--	--
殖利率 (%)	6.93	4.26	2.38	--	--

* 以目前股本計算


資料來源：CMoney；永豐投顧研究處整理 · Nov. 2024

營運基本資料


同業比較

代號	公司	投資建議	目前股價	市值(億)	稅後 EPS		PE		PB	
					2023	2024	2023	2024	2023	2024


近三年單月營收狀況




近三年單季營收 VS 毛利率趨勢圖




負債比率 VS 存貨周轉天數



歷史 PE 圖



歷史 PB 圖



臺北	永豐證券投資顧問股份有限公司 臺北市忠孝西路一段 80 號 14 樓 電話：(886-2) 2361-0868	永豐金證券股份有限公司 臺北市重慶南路一段 2 號 17 樓 電話：(886-2) 2311-4345
香港	永豐金證券(亞洲)有限公司 香港銅鑼灣新寧道 1 號 7 樓 電話：(852) 2586-8288	
上海	永豐金證券(亞洲)有限公司上海代表處 中國上海市浦東新區世紀大道 1528 號陸家嘴基金大廈 1903A-2 室 電話：(86-21) 6228-8220	

責任聲明

本報告內容僅供參考，客戶應審慎考量本身之需求與投資風險，本公司恕不負任何法律責任，亦不作任何保證。本報告中之內容或有取材於本公司認可之來源，但並不保證其真實性或完整性；報告中所有資訊或預估，變更時本公司將不作預告，若資料內容有未盡完善之處，恕不負責。此外，非經本公司同意，不得將本報告加以複製或轉載。

110 年金管投顧新字第 024 號

SinoPac 投資評等

B：Buy 買進：未來 12 個月該股票表現將優於大盤

N：Neutral 中立：未來 12 個月該股票表現將與大盤一致

S：Sell 賣出：未來 12 個月該股票表現將落後大盤

Analyst Certification:

For each company mentioned in this research report, the respective analyst(s) who cover the company certifies (certify) that all of the views expressed in this research report accurately reflect his (their) personal views about any and all of the subject issuer(s) or securities. The analyst(s) also certifies (certify) that no part of her (their) compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

SinoPac Research Stock Rating System:

Buy: We think the stock will outperform the broader market over the next 12 months.

Neutral: We think the stock will perform in line with the broader market over the next 12 months.

Sell: We think the stock will underperform the market over the next 12 months.

Global Disclaimer:**Important Disclosures for U.S. Persons**

This research report was prepared by SinoPac Securities Corporation (SinoPac), a company authorized to engage in securities activities in Taiwan. SinoPac is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Auerbach Grayson & Company, 20 Wall West 55th Street, New York, NY 10019, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SinoPac. Auerbach Grayson & Company accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Auerbach Grayson & Company and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Ownership and Material Conflicts of Interest

Auerbach Grayson & Company or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Auerbach Grayson & Company, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Auerbach Grayson & Company is not aware of any material conflict of interest as of the date of this publication.

Compensation and Investment Banking Activities

Auerbach Grayson & Company or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither SinoPac nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

SinoPac may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of SinoPac.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by SinoPac with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of SinoPac and SinoPac accepts no liability whatsoever for the actions of third parties in this respect.